Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin icodec vs insulin glargine in type 2 diabetes on basal-bolus regimen
NCT04880850Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Haemoglobin at 26 weeks. Started May 2021; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04880850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880850.